Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.

@article{Iwamoto2008SafetyTA,
  title={Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.},
  author={Marian Iwamoto and Larissa A. Wenning and Amelia S Petry and Martine Laethem and Marina De Smet and James T. Kost and Shelia A Merschman and Kim M. Strohmaier and Steven Ramael and Kenneth C. Lasseter and Julie A. Stone and Keith M. Gottesdiener and John J. Wagner},
  journal={Clinical pharmacology and therapeutics},
  year={2008},
  volume={83 2},
  pages={
          293-9
        }
}
Raltegravir is a novel human immunodeficiency virus-1 integrase inhibitor with potent in vitro activity (95% inhibitory concentration (IC95)=33 nM in 50% human serum). Three double-blind, randomized, placebo-controlled, pharmacokinetic, safety, and tolerability studies were conducted: (1) single-dose escalation study (10-1,600 mg), (2) multiple-dose escalation study (100-800 mg q12 h x 10 days), and (3) single-dose female study (400 mg). Raltegravir was rapidly absorbed with a terminal half… CONTINUE READING
BETA

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 76 CITATIONS, ESTIMATED 53% COVERAGE

145 Citations

0102030'10'13'16'19
Citations per Year
Semantic Scholar estimates that this publication has 145 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
SHOWING 1-10 OF 15 REFERENCES

on Antiretroviral Guidelines for Adults and Adolescents—A working group of the Office of AIDS Research Advisory Council (OARAC)

  • DHHS Pane
  • Guidelines for the Use of Antiretroviral Agents…
  • 2008
1 Excerpt

Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus [abstract 105a LB

  • D Cooper
  • Presented at 14th Conference on Retroviruses and…
  • 2007

Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus [abstract 105b LB

  • R Steigbigel
  • Presented at 14th Conference on Retroviruses and…
  • 2007

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomized controlled trial

  • B Grinsztejn
  • Lancet 369,
  • 2007

Absorption, metabolism and excretion of MK-0518, a potent HIV-1 integrase inhibitor, in healthy male volunteers [abstract A-372

  • K Kassahun
  • In 46th Interscience Conference on Antimicrobial…
  • 2006
2 Excerpts

Biochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitor [abstract THAA0302

  • Miller, M.D
  • In XVI International AIDS Conference,
  • 2006
1 Excerpt

Discovery of MK-0518 a novel, potent and selective HIV integrase inhibitor in phase III clinical trials [abstract THPE0020

  • V Summa
  • In XVI International AIDS Conference,
  • 2006
1 Excerpt

Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, as part of combination ART in treatment naive HIV-1 infected patients [abstract THLB0214

  • M Markowitz
  • In XVI International AIDS Conference,
  • 2006

Similar Papers

Loading similar papers…